AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens

Acute myeloid leukemia (AML) is a disease that mainly affects elderly patients who are more often unfit for intensive chemotherapy (median age of diagnosis is 68). The regimens, including venetoclax, a highly specific BCL-2 (B-cell lymphoma-2) inhibitor, are a common alternative because of their saf...

Full description

Bibliographic Details
Main Authors:	Szymon Milnerowicz, Julia Maszewska, Paulina Skowera, Magdalena Stelmach, Monika Lejman
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	International Journal of Molecular Sciences
Subjects:	acute myeloid leukemia (AML) tyrosine kinase inhibitors (TKI) FLT3 (FMS-like tyrosine kinase-3) inhibitors FLT3-internal tandem duplication (ITD) BCL-2 (B-cell lymphoma-2) inhibitors
Online Access:	https://www.mdpi.com/1422-0067/24/21/15849

Similar Items

Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
by: Kateryna Fedorov, et al.
Published: (2023-04-01)

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study
by: Hind Dehbi, et al.
Published: (2013-01-01)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
by: Sebastian Scholl, et al.
Published: (2020-11-01)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
by: Jessica K. Altman, et al.
Published: (2021-02-01)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-09-01)

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML
by: Maya Graham Pedersen, et al.
Published: (2022-09-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
by: Karam Ashouri, et al.
Published: (2024-04-01)

The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
by: Belen Lopez-Millan, et al.
Published: (2022-03-01)

FLT3 inhibitors in acute myeloid leukemia
by: Mei Wu, et al.
Published: (2018-12-01)

Role of Biomarkers in FLT3 AML
by: Nitika, et al.
Published: (2022-02-01)

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
by: Tecik M, et al.
Published: (2022-11-01)

Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
by: Sankaranarayan Kannan, et al.
Published: (2022-04-01)

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
by: Kyriakos P. Papadopoulos, et al.
Published: (2018-08-01)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
by: Tobias R. Haage, et al.
Published: (2023-05-01)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
by: Motoki Eguchi, et al.
Published: (2020-07-01)

Evaluation of Cytogenetic Changes and FLT3 mutations in Patients with Acute Promyelocytic Leukemia
by: Marjan Yaghmaie, et al.
Published: (2010-09-01)

Evaluation of Cytogenetic Changes and FLT3 mutations in Patients with Acute Promyelocytic Leukemia
by: Marjan Yaghmaie, et al.
Published: (2010-07-01)

Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.
by: Özden Hatırnaz Ng, et al.
Published: (2022-05-01)

Autophagy Targeting and Hematological Mobilization in FLT3-ITD Acute Myeloid Leukemia Decrease Repopulating Capacity and Relapse by Inducing Apoptosis of Committed Leukemic Cells
by: Marine Dupont, et al.
Published: (2022-01-01)

Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia
by: Andrea Duminuco, et al.
Published: (2022-09-01)

Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation
by: Shintaro Izumi, et al.
Published: (2020-09-01)

The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
by: Bernhard Moser, et al.
Published: (2021-08-01)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
by: Ahmad S. Alotaibi, et al.
Published: (2020-10-01)

Comparison of high-resolution melting analysis with direct sequencing for detection of FLT3-TKD, FLT3-ITD and WT1 mutations in acute myeloid leukemia
by: Aida Mahmoudi, et al.
Published: (2021-01-01)

Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks
by: Isabel Bär, et al.
Published: (2020-11-01)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
by: Varvara Maiorova, et al.
Published: (2023-04-01)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
by: Pashtoon M. Kasi, et al.
Published: (2016-01-01)

Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity
by: Chen Yun, et al.
Published: (2012-07-01)

SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
by: Guo Yao, et al.
Published: (2012-12-01)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
by: Michael Loschi, et al.
Published: (2021-05-01)

19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)
by: Joshua J. Lara, et al.
Published: (2022-11-01)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
by: Tristan E. Knight, et al.
Published: (2022-07-01)

Quizartinib (AC220): a promising option for acute myeloid leukemia
by: Zhou F, et al.
Published: (2019-04-01)

Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
by: Pierre-Yves Dumas, et al.
Published: (2020-07-01)

Are cup-like blasts specific to AML patients with FLT3 ITD and a normal karyotype? An ALL case report and review of the literature
by: Özgür Mehtap, et al.
Published: (2011-06-01)

Are cup-like blasts specific to AML patients with FLT3 ITD and a normal karyotype? An ALL case report and review of the literature
by: Özgür Mehtap, et al.
Published: (2011-05-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
by: Silvia Waldeck, et al.
Published: (2020-04-01)

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat <i>FLT3</i>-Mutated AML Patients
by: Matteo Molica, et al.
Published: (2023-05-01)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
by: Franziska Schmidt, et al.
Published: (2022-11-01)